文献速递肝病

吡格列酮在有或无2型糖尿病的非酒精性脂肪性肝炎患者中的疗效对比

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-12-07

结果显示吡格列酮在两组均有效,但2型糖尿病组肝纤维化改善和脂肪组织胰岛素敏感性提升更显著。

要点

  • 吡格列酮45 mg/d治疗18个月对伴或不伴2型糖尿病的NASH患者均有效。
  • 2型糖尿病组NASH缓解率44%,糖尿病前期组26%。
  • 仅2型糖尿病组观察到肝纤维化较基线显著改善(P = .035)。

核心结论

  • 吡格列酮在有或无2型糖尿病的NASH患者中均有效,但在2型糖尿病患者中降低肝纤维化和提高脂肪组织胰岛素敏感性的幅度显著大于糖尿病前期患者。
  • 需要进一步研究确定吡格列酮减轻2型糖尿病患者肝病的机制。

研究设计与样本

  • 前瞻性研究,从2008年至2014年于德克萨斯州圣安东尼奥一般人群招募经活检证实的NASH成人,52例伴2型糖尿病,49例伴糖尿病前期。
  • 经过约4周导入期完成基线测量后,受试者随机接受吡格列酮45 mg/d或安慰剂治疗18个月,随后重复所有基线检查。
  • 主要结局为非酒精性脂肪性肝病活动度评分降低≥2分(至少2个组分)且纤维化不恶化,以与安慰剂的差异表示。

主要发现

  • 主要结局在2型糖尿病组达到48%,无糖尿病组达到46%。
  • NASH缓解在2型糖尿病组为44%,无糖尿病组为26%。
  • 肝纤维化较基线的显著降低仅见于2型糖尿病组(P = .035)。
  • 肝内甘油三酯含量在糖尿病组降低11% ± 2%,无糖尿病组降低9% ± 2%(P = .62);丙氨酸氨基转移酶血浆水平在糖尿病组降低50 ± 10 U/L,无糖尿病组降低36 ± 5 U/L(P = .22)。
  • 吡格列酮与脂肪组织胰岛素敏感性的显著改善相关,2型糖尿病组优于无糖尿病组(P < .001),但肝脏(P = .49)和骨骼肌(P = .32)胰岛素敏感性反应的差异无统计学意义。

局限性

  • 需要进一步研究确定吡格列酮减轻2型糖尿病患者肝病的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Pioglitazone is effective for long-term treatment of patients with nonalcoholic steatohepatitis (NASH) with prediabetes or type 2 diabetes. However, it is not clear how the presence of type 2 diabetes affects the drug's efficacy. We compared metabolic and histologic responses to pioglitazone in patients with NASH and prediabetes vs type 2 diabetes. METHODS: We performed a prospective study of adults with biopsy-proven NASH (52 with type 2 diabetes and 49 with prediabetes), enrolled from the general population of San Antonio, Texas, from 2008 through 2014. After a run-in period of approximately 4 weeks, when all baseline measurements were made (liver magnetic resonance proton spectroscopy, euglycemic insulin clamp with glucose turnover measurements, dual-energy absorptiometry, and liver biopsy), subjects were randomly assigned to groups given pioglitazone or placebo (45 mg/d) for 18 months; all procedures performed at baseline were then repeated. The primary outcome was a reduction in nonalcoholic fatty liver disease activity score of 2 points or more (for at least 2 components) without worsening of fibrosis (and expressed as difference vs placebo). Secondary outcomes included NASH resolution, individual histologic components, intrahepatic triglyceride content (measured by 1H magnetic resonance spectroscopy), and insulin sensitivity (measured by euglycemic insulin clamp). RESULTS: The primary outcome was met by 48% of patients with type 2 diabetes vs 46% without diabetes. Resolution of NASH was achieved in 44% of patients with type 2 diabetes vs 26% without diabetes. A significant reduction in fibrosis, from baseline, was observed only in patients with type 2 diabetes (P = .035). Intrahepatic triglyceride content was reduced by 11% ± 2% in patients with diabetes vs a reduction of 9% ± 2% in patients without diabetes (P = .62); the plasma level of alanine aminotransferase was reduced by 50 ± 10 U/L in patients with diabetes vs a reduction of 36 ± 5 U/L in patients without diabetes (P = .22). Pioglitazone was associated with a significantly greater insulin sensitivity in adipose tissue of patients with diabetes vs without diabetes (P < .001), but nonsignificant differences in responses in hepatic (P = .49) and skeletal muscle (P = .32) insulin sensitivity. CONCLUSIONS: In a prospective study, we found pioglitazone to be effective in patients with and without type 2 diabetes. However, pioglitazone reduced liver fibrosis and increased adipose tissue insulin sensitivity at significantly greater levels in patients with type 2 diabetes than in patients with prediabetes. Further studies are needed to determine the mechanisms by which pioglitazone reduces liver disease in patients with type 2 diabetes. ClinicalTrials.gov: NCT00994682.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bril F, Kalavalapalli S, Clark VC, et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2017. PMID: 29223443. doi:10.1016/j.cgh.2017.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。